SCHEMBL7274699

SCHEMBL7274699

CCCC(OS(C)(=O)=O)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
CHRM1 P11229 1/20 0.43
AKR1A1 P14550 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43
DRD3 P35462 1/20 0.43
SLC6A3 Q01959 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PPARG P37231 4/20 0.40
PPARA Q07869 4/20 0.40
CYP3A4 P08684 2/20 0.37
TSHR P16473 2/20 0.37
NFKB1 P19838 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9350162 1.00 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL2327532 1.00 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL18704278 0.88 CA2 (0.44) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL2323492 0.88 CA2 (0.44) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL8863767 0.85 GPR84 (0.48) GRIK1GRIK2CA2GPR84FFAR1
SCHEMBL8612175 0.85 GPR84 (0.48) GRIK1GRIK2CA2GPR84FFAR1
SCHEMBL3958813 0.83 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL2322915 0.83 ALDH1A1 (0.39) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL4745489 0.83 ALDH1A1 (0.39) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL3199746 0.83 ALDH1A1 (0.39) HDAC1HDAC2CHRM1AKR1A1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016016446-A1 PROCESS FOR PREPARING 2-FLUOROPROPIONALDEHYDE SANDOZ AG (CH) 2016-02-04 WO claimed
EP-3773573-A1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) Morphic Therapeutic, Inc. (US) 2021-02-17 EP disclosed
WO-2019200202-A1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) MORPHIC THERAPEUTIC, INC. (US) 2019-10-17 WO disclosed
WO-2016016446-A1 PROCESS FOR PREPARING 2-FLUOROPROPIONALDEHYDE SANDOZ AG (CH) 2016-02-04 WO disclosed
EP-2739625-A1 CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2014-06-11 EP disclosed
WO-2013022814-A1 CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-14 WO disclosed
EP-0758328-A1 ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING BTG INTERNATIONAL LIMITED (GB) 1997-02-19 EP disclosed
WO-1995030673-A1 ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING BRITISH TECHNOLOGY GROUP LIMITED (GB) 1995-11-16 WO disclosed
EP-0222413-B1 NOVEL FORSKOLIN DERIVATIVES NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1992-02-05 EP disclosed
US-4954642-A INOTROPIC, HYPOTENSIVE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1990-09-04 US disclosed
EP-0271287-A2 Quinoline dioic acids and amides MERCK FROSST CANADA INC. (CA) 1988-06-15 EP disclosed
EP-0222413-A2 Novel forskolin derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1987-05-20 EP disclosed